Penile cancer: Current therapy and future directions

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1179-1189

  Sonpavde, G ^a   Pagliaro, L C ^b   Buonerba, C ^c   Dorff, T B ^d   Lee, R J ^e   Di Lorenzo, G ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Biologic agents; Chemotherapy; Combined modality therapy; Molecular targets; Penile cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IMIQUIMOD; IRINOTECAN; K RAS PROTEIN; METHOTREXATE; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROSTAGLANDIN E SYNTHASE 1; PROTEIN KINASE B; SORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; BRACHYTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CIRCUMCISION; DISTANT METASTASIS; DRUG RESPONSE; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION; LASER SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PENIS AMPUTATION; PENIS CANCER; PENIS CARCINOMA; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SARCOMATOID CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VIRUS CARCINOGENESIS; WATCHFUL WAITING;

CIRCUMCISION, MALE; COMBINED MODALITY THERAPY; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHATIC METASTASIS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84876245472     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds635     Document Type: Review

References (150)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J et al. Incidence trends in primary malignant penile cancer. Urol Oncol 2007; 25: 361-367.
3. Ornellas AA. Management of penile cancer. J Surg Oncol 2008; 97: 199-200.
4. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004; 5: 240-247.
5. Goodman MT, Hernandez BY, Shvetsov YB. Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995-2003. Cancer Epidemiol Biomarkers Prev 2007; 16: 1833-1839.
6. Hernandez BY, Barnholtz-Sloan J, German RR et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008; 113: 2883-2891.
7. Schoen EJ. The relationship between circumcision and cancer of the penis. CA Cancer J Clin 1991; 41: 306-309.
8. Kochen M, McCurdy S. Circumcision and the risk of cancer of the penis. A life-table analysis. Am J Dis Child 1980; 134: 484-486.
9. Dillner J, von Krogh G, Horenblas S et al. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000; 00: 189-193.
10. Clouston D, Hall A, Lawrentschuk N. Penile lichen sclerosus (balanitis xerotica obliterans). BJU Int 0000; 108(Suppl 2): 14-19.
11. Schmauz R, Jain DK. Geographical variation of carcinoma of the penis in Uganda. Br J Cancer 1971; 25: 25-32.
12. Maden C, Sherman KJ, Beckmann AM et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85: 19-24.
13. Van Howe RS, Hodges FM. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol 2006; 20: 1046-1054.
14. Waskett JH, Morris BJ. Re: 'RS Van Howe, FM Hodges. The carcinogenicity of smegma: debunking a myth.' An example of myth and mythchief making?. J Eur Acad Dermatol Venereol 2008; 22: 131; author reply 131-132.
15. Heideman DA, Waterboer T, Pawlita M et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007; 25: 4550-4556.
16. Bleeker MC, Heideman DA, Snijders PJ et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009; 27: 141-150.
17. Bezerra AL, Lopes A, Santiago GH et al. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001; 91: 2315-2321.
18. Backes DM, Kurman RJ, Pimenta JM et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20: 449-457.
19. Gregoire L, Cubilla AL, Reuter VE et al. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst 1995; 87: 1705-1709.
20. Miralles-Guri C, Bruni L, Cubilla AL et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62: 870-878.
21. Rubin MA, Kleter B, Zhou M et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001; 159: 1211-1218.
22. Mannweiler S, Sygulla S, Beham-Schmid C et al. Penile carcinogenesis in a lowincidence area: a clinicopathologic and molecular analysis of 115 invasive carcinomas with special emphasis on chronic inflammatory skin diseases. Am J Surg Pathol 0000; 35: 998-1006.
23. Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105-1112.
24. Backes DM, Bleeker MC, Meijer CJ et al. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. Int J Cancer 0000; 130: 1888-1897.
25. Barroso LF, II, Wilkin T. Human papillomavirus vaccination in males: the state of the science. Curr Infect Dis Rep 0000; 13: 175-181.
26. Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
27. Daling JR, Madeleine MM, Johnson LG et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005; 116: 606-616.
28. Hellberg D, Valentin J, Eklund T et al. Penile cancer: is there an epidemiological role for smoking and sexual behaviour?. Br Med J (Clin Res Ed) 1987; 295: 1306-1308.
29. Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990; 322: 1093-1097.
30. Heyns CF, Mendoza-Valdes A, Pompeo AC. Diagnosis and staging of penile cancer. Urology 76: S15-23.
31. Burgers JK, Badalament RA, Drago JR. Penile cancer. Clinical presentation, diagnosis, and staging. Urol Clin North Am 1992; 19: 247-256.
32. Hegarty PK, Kayes O, Freeman A et al. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98: 526-531.
33. Schlenker B, Scher B, Tiling R et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol 0000; 30: 55-59.
34. Graafland NM, Leijte JA, Valdes Olmos RA et al. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol 2009; 56: 339-345.
35. Souillac I, Rigaud J, Ansquer C et al. Prospective evaluation of (18)Ffluorodeoxyglucose positron emission tomography-computerized tomography to assess inguinal lymph node status in invasive squamous cell carcinoma of the penis. J Urol 0000; 187: 493-497.
36. Rosevear HM, Williams H, Collins M et al. Utility of (18)F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol 2012; 30: 723-6.
37. Leijte JA, Graafland NM, Valdes Olmos RA et al. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int 2009; 104: 640-644.
38. Kayes O, Minhas S, Allen C et al. The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 2007; 51: 1313-1318; discussion 1318-1319.
39. Cubilla AL, Reuter V, Velazquez E et al. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol 2001; 9: 111-120.
40. Eble J, Sauter G, Epstein J et al. (eds), World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, Chapter 5. Lyon: IARC Press 2004; 281-290.
41. Ornellas AA, Seixas AL, Marota A et al. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994; 151: 1244-1249.
42. Stankiewicz E, Kudahetti SC, Prowse DM et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol 2009; 22: 1160-1168.
43. Hainsworth JD, Meluch AA, Litchy S et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 2005; 103: 2298-2303.
44. Pizzocaro G, Algaba F, Horenblas S et al. EAU penile cancer guidelines 2009. Eur Urol 0000; 57: 1002-1012.
45. Cubilla AL, Lloveras B, Alejo M et al. The basaloid cell is the best tissue marker for human papillomavirus in invasive penile squamous cell carcinoma: a study of 202 cases from Paraguay. Am J Surg Pathol 0000; 34: 104-114.
46. Cubilla AL, Lloveras B, Alejo M et al. Value of p16(INK)(4)(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am J Surg Pathol 0000; 35: 253-261.
47. Lavens N, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. Curr Oncol 0000; 17: 4-6.
48. Dorff TB, Schwartz R, Ma Y et al. EGFR, TS, and ERCC1 expression in penile squamous cancer. J Clin Oncol 2011; 29(Suppl 7): 219.
49. Kayes O, Ahmed HU, Arya M et al. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8: 420-429.
50. Valverde CM, Hernandez-Losa J, Ferrandiz-Pulido C et al. BRAF and KRAS mutations in penile cancer and their correlation with clinical features. J Clin Oncol 2011; 29(Suppl 7): 221.
51. Andersson P, Kolaric A, Windahl T et al. PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J Urol 2008; 179: 2030-2034.
52. Bamford S, Dawson E, Forbes S et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-358.
53. Stankiewicz E, Prowse DM, Ng M et al. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PLoS One 6: e17517.
54. Guerrero D, Guarch R, Ojer A et al. Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int 2008; 102: 747-755.
55. Poetsch M, Hemmerich M, Kakies C et al. Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 0000; 458: 221-229.
56. Stankiewicz E, Prowse DM, Ktori E et al. The retinoblastoma protein/p16 INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma. Histopathology 0000; 58: 433-439.
57. Lopes A, Bezerra AL, Pinto CA et al. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol 2002; 168: 81-86.
58. Gunia S, Kakies C, Erbersdobler A et al. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. J Clin Pathol 0000; 65: 232-236.
59. Zhu Y, Zhou XY, Yao XD et al. The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery. BJU Int 2007; 100: 204-208.
60. Kayes OJ, Loddo M, Patel N et al. DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res 2009; 15: 7335-7344.
61. Alves G, Fiedler W, Guenther E et al. Determination of telomerase activity in squamous cell carcinoma of the penis. Int J Oncol 2001; 18: 67-70.
62. Nascimento Pde S, Ornellas AA, Campos MM et al. Bax and bcl-2 imbalance and HPB infection in penile tumors and adjacent tissues. Prog Urol 2004; 14: 353-359.
63. Alves G, Heller A, Fiedler W et al. Genetic imbalances in 26 cases of penile squamous cell carcinoma. Genes Chromosomes Cancer 2001; 31: 48-53.
64. Golijanin D, Tan JY, Kazior A et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res 2004; 10: 1024-1031.
65. Zhu Y, Li H, Yao XD et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int 2010; 85: 334-340.
66. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. UICC International Union Against Cancer. 7th edition. Oxford, UK: Wiley-Blackwell 2009; 239-242.
67. Graafland NM, van Boven HH, van Werkhoven E et al. Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol 2010; 184: 1347-1353.
68. Ficarra V, Zattoni F, Artibani W et al. Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. J Urol 2006; 175: 1700-1704; discussion 1704-1705.
69. Kattan MW, Ficarra V, Artibani W et al. Nomogram predictive of cancer specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. J Urol 2006; 175: 2103-2108; discussion 2108.
70. Zini L, Cloutier V, Isbarn H et al. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. Clin Cancer Res 2009; 15: 1013-1018.
71. de Kernion JB, Tynberg P, Persky L et al. Proceedings: carcinoma of the penis. Cancer 1973; 32: 1256-1262.
72. Ornellas AA, Nobrega BL, Wei Kin Chin E et al. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol 2008; 180: 1354-1359.
73. Sarin R, Norman AR, Steel GG et al. Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. Int J Radiat Oncol Biol Phys 1997; 38: 713-722.
74. Ficarra V, Akduman B, Bouchot O et al. Prognostic factors in penile cancer. Urology 2010; 76: S66-S73.
75. Graafland NM, Lam W, Leijte JA et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol 2010; 58: 742-747.
76. Svatek RS, Munsell M, Kincaid JM et al. Association between lymph node density and disease specific survival in patients with penile cancer. J Urol 2009; 182: 2721-2727.
77. Lopes A, Hidalgo GS, Kowalski LP et al. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J Urol 1996; 156: 1637-1642.
78. Guimaraes GC, Lopes A, Campos RS et al. Front pattern of invasion in squamous cell carcinoma of the penis: new prognostic factor for predicting risk of lymph node metastases. Urology 2006; 68: 148-153.
79. Slaton JW, Morgenstern N, Levy DA et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol 2001; 165: 1138-1142.
80. Thuret R, Sun M, Abdollah F et al. Conditional survival predictions after surgery for patients with penile carcinoma. Cancer 2011; 117: 3723-3730.
81. Thuret R, Sun M, Abdollah F et al. Tumor grade improves the prognostic ability of American Joint Committee on Cancer stage in patients with penile carcinoma. J Urol 2011; 185: 501-507.
82. Ficarra V, Zattoni F, Cunico SC et al. Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis: Gruppo Uro-Oncologico del Nord Est (Northeast Uro-Oncological Group) Penile Cancer data base data. Cancer 2005; 103: 2507-2516.
83. Soria JC, Fizazi K, Piron D et al. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol 1997; 8: 1089-1098.
84. Mannweiler S, Sygulla S, Tsybrovskyy O et al. Clear-cell differentiation and lymphatic invasion, but not the revised TNM classification, predict lymph node metastases in pT1 penile cancer: a clinicopathologic study of 76 patients from a low incidence area. Urol Oncol 2012 Mar 13 [epub ahead of print].
85. Campos RS, Lopes A, Guimaraes GC et al. E-cadherin, MMP-2, and MMP-9 as prognostic markers in penile cancer: analysis of 125 patients. Urology 2006; 67: 797-802.
86. Protzel C, Kakies C, Kleist B et al. Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch 2008; 452: 369-375.
87. Protzel C, Knoedel J, Zimmermann U et al. Expression of proliferation marker Ki67 correlates to occurrence of metastasis and prognosis, histological subtypes and HPV DNA detection in penile carcinomas. Histol Histopathol 2007; 22: 1197-1204.
88. Protzel C, Richter M, Poetsch M et al. The role of annexins I, II and IV in tumor development, progression and metastasis of human penile squamous cell carcinomas. World J Urol 2011; 29: 393-398.
89. Lont AP, Kroon BK, Horenblas S et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006; 119: 1078-1081.
90. Gunia S, Erbersdobler A, Hakenberg OW et al. p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multiinstitutional study. J Urol 2012; 187: 899-907.
91. Feldman AS, McDougal WS. Long-term outcome of excisional organ sparing surgery for carcinoma of the penis. J Urol 2011; 186: 1303-1307.
92. Minhas S, Kayes O, Hegarty P et al. What surgical resection margins are required to achieve oncological control in men with primary penile cancer?. BJU Int 2005; 96: 1040-1043.
93. Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol 2010; 183: 2227-2232.
94. Protzel C, Alcaraz A, Horenblas S et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol 2009; 55: 1075-1088.
95. Heyns CF, Fleshner N, Sangar V et al. Management of the lymph nodes in penile cancer. Urology 2010; 76: S43-57.
96. Pompeo AC. Extended lymphadenectomy in penile cancer. Can J Urol 2005; 12(Suppl 1): 30-36; discussion 97-98.
97. Kroon BK, Horenblas S, Lont AP et al. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005; 173: 816-819.
98. Lont AP, Kroon BK, Gallee MP et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007; 177: 947-952; discussion 952.
99. Ornellas AA, Kinchin EW, Nobrega BL et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute longterm experience. J Surg Oncol 2008; 97: 487-495.
100. Spiess PE, Izawa JI, Bassett R et al. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol 2007; 177: 2157-2161.
101. Izawa J, Kedar D, Wong F et al. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol 2005; 12(Suppl 1): 24-29.
102. Hungerhuber E, Schlenker B, Frimberger D et al. Lymphoscintigraphy in penile cancer: limited value of sentinel node biopsy in patients with clinically suspicious lymph nodes. World J Urol 2006; 24: 319-324.
103. Neto AS, Tobias-Machado M, Ficarra V et al. Dynamic sentinel node biopsy for inguinal lymph node staging in patients with penile cancer: a systematic review and cumulative analysis of the literature. Ann Surg Oncol 2011; 18: 2026-2034.
104. Graafland NM, Valdes Olmos RA, Meinhardt W et al. Nodal staging in penile carcinoma by dynamic sentinel node biopsy after previous therapeutic primary tumour resection. Eur Urol 2010; 58: 748-751.
105. Pettaway CA, Pisters LL, Dinney CP et al. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol 1995; 154: 1999-2003.
106. Tobias-Machado M, Tavares A, Ornellas AA et al. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol 2007; 177: 953-957; discussion 958.
107. Leijte JA, Kirrander P, Antonini N et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 2008; 54: 161-168.
108. Franks KN, Kancherla K, Sethugavalar B et al. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol 2011; 186: 524-529.
109. Chen MF, Chen WC, Wu CT et al. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol 2004; 22: 60-66.
110. Mistry T, Jones RW, Dannatt E et al. A 10-year retrospective audit of penile cancer management in the UK. BJU Int 2007; 100: 1277-1281.
111. Gotsadze D, Matveev B, Zak B et al. Is conservative organ-sparing treatment of penile carcinoma justified?. Eur Urol 2000; 38: 306-312.
112. Azrif M, Logue JP, Swindell R et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol) 2006; 18: 320-325.
113. Zouhair A, Coucke PA, Jeanneret W et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis?. Eur J Cancer 2001; 37: 198-203.
114. Rozan R, Albuisson E, Giraud B et al. Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients). Radiother Oncol 1995; 36: 83-93.
115. de Crevoisier R, Slimane K, Sanfilippo N et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 2009; 74: 1150-1156.
116. Crook J, Grimard L, Tsihlias J et al. Interstitial brachytherapy for penile cancer: an alternative to amputation. J Urol 2002; 167: 506-511.
117. Pedrick TJ, Wheeler W, Riemenschneider H. Combined modality therapy for locally advanced penile squamous cell carcinoma. Am J Clin Oncol 1993; 16: 501-505.
118. Eliason M, Bowen G, Bowen A et al. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol 2009; 145: 950-952.
119. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054.
120. van Doorn HC, Ansink A, Verhaar-Langereis M et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev 2006; 19: CD003752.
121. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988; 27: 823-824.
122. Leijte JA, Kerst JM, Bais E et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007; 52: 488-494.
123. Hakenberg OW, Nippgen JB, Froehner M et al. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006; 98: 1225-1227.
124. Bermejo C, Busby JE, Spiess PE et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177: 1335-1338.
125. Pagliaro LC, Williams DL, Daliani D et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28: 3851-3857.
126. Graafland NM, Valdes Olmos RA, Teertstra HJ et al. 18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results. Eur J Nucl Med Mol Imaging 2010; 37: 1474-1480.
127. Maiche AG. Adjuvant treatment using bleomycin in squamous cell carcinoma of penis: study of 19 cases. Br J Urol 1983; 55: 542-544.
128. Protzel C, Ruppin S, Milerski S et al. The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics. Urologe A 2009; 48: 1495-1498.
129. Gagliano RG, Blumenstein BA, Crawford ED et al. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 1989; 141: 66-67.
130. Corral DA, Sella A, Pettaway CA et al. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 1998; 160: 1770-1774.
131. Dexeus FH, Logothetis CJ, Sella A et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 1991; 146: 1284-1287.
132. Haas GP, Blumenstein BA, Gagliano RG et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161: 1823-1825.
133. Pettaway CA, Pagliaro L, Theodore C et al. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 2010; 76: S58-S65.
134. Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546-551.
135. Trabulsi EJ, Hoffman-Censits J. Chemotherapy for penile and urethral carcinoma. Urol Clin North Am 2010; 37: 467-474.
136. Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65: 433-438.
137. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147: 630-632.
138. Di Lorenzo G, Buonerba C, Federico P et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012 September 10 [epub ahead of print].
139. Necchi A, Nicolai N, Piva L et al. A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of the penis: a single institution series. Ann Oncol 2010; 21(Suppl 8): viii271-viii303, abstr 939P.
140. Theodore C, Skoneczna I, Bodrogi I et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19: 1304-1307.
141. Power DG, Galvin DJ, Cuffe S et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27: 187-190.
142. Di Lorenzo G, Federico P, Buonerba C et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60: 1280-1284.
143. Carthon BC, Pettaway C, Pagliaro LC. Epidermal growth factor receptor (EGFR) targeted therapy in advanced metastatic squamous cell carcinoma (AMSCC) of the penis: updates and molecular analyses. J Clin Oncol 2010; 28 (Suppl); abstr e15022.
144. Necchi A, Nicolai N, Colecchia M et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011; 29: e650-e652.
145. Rescigno P, Matano E, Raimondo L et al. Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs 2012; 23: 573-577.
146. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113.
147. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
148. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
149. Lucky MA, Rogers B, Parr NJ. Referrals into a dedicated British penile cancer centre and sources of possible delay. Sex Transm Infect 2009; 85: 527-530.
150. Ivy SP, Siu LL, Garrett-Mayer E et al. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010; 16: 1726-1736.